Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer

G. Wang, J. Qiu, R. Wang, A. Krause, J. L. Boyer, N. R. Hackett, Ronald Crystal

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10αHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2+ tumor cell lines. A single administration of AAVrh.10αHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2 tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.

Original languageEnglish
Pages (from-to)559-570
Number of pages12
JournalCancer Gene Therapy
Volume17
Issue number8
DOIs
Publication statusPublished - 1 Aug 2010
Externally publishedYes

Fingerprint

Dependovirus
Anti-Idiotypic Antibodies
Genes
Antibodies, Monoclonal, Humanized
Neoplasms
Growth
Tumor Cell Line
Heterografts
Nude Mice
Primates
Therapeutics
Complementary DNA
Monoclonal Antibodies
Light
Survival
Trastuzumab
Proteins
human ERBB2 protein

Keywords

  • Adeno-associated virus
  • Breast cancer
  • Gene delivery
  • Herceptin
  • Trastuzumab

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. / Wang, G.; Qiu, J.; Wang, R.; Krause, A.; Boyer, J. L.; Hackett, N. R.; Crystal, Ronald.

In: Cancer Gene Therapy, Vol. 17, No. 8, 01.08.2010, p. 559-570.

Research output: Contribution to journalArticle

Wang, G. ; Qiu, J. ; Wang, R. ; Krause, A. ; Boyer, J. L. ; Hackett, N. R. ; Crystal, Ronald. / Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer. In: Cancer Gene Therapy. 2010 ; Vol. 17, No. 8. pp. 559-570.
@article{7be49a0cddf14ea59a5364301528ca14,
title = "Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer",
abstract = "Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10αHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2+ tumor cell lines. A single administration of AAVrh.10αHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2 tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.",
keywords = "Adeno-associated virus, Breast cancer, Gene delivery, Herceptin, Trastuzumab",
author = "G. Wang and J. Qiu and R. Wang and A. Krause and Boyer, {J. L.} and Hackett, {N. R.} and Ronald Crystal",
year = "2010",
month = "8",
day = "1",
doi = "10.1038/cgt.2010.11",
language = "English",
volume = "17",
pages = "559--570",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer

AU - Wang, G.

AU - Qiu, J.

AU - Wang, R.

AU - Krause, A.

AU - Boyer, J. L.

AU - Hackett, N. R.

AU - Crystal, Ronald

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10αHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2+ tumor cell lines. A single administration of AAVrh.10αHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2 tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.

AB - Trastuzumab (Herceptin) is a recombinant humanized monoclonal antibody (mAb) directed against an extracellular region of the human epidermal growth-factor receptor type 2 (HER2) protein. We hypothesized that a single adeno-associated virus (AAV)-mediated genetic delivery of an anti-HER2 antibody should be effective in mediating long-term production of anti-HER2 and in suppressing the growth of human tumors in a xenograft model in nude mice. The adeno-associated virus gene transfer vector AAVrh.10αHER2 was constructed based on a non-human primate AAV serotype rh.10 to express the complementary DNAs for the heavy and light chains of mAb 4D5, the murine precursor to trastuzumab. The data show that genetically transferred anti-HER2 selectively bound human HER2 protein and suppressed the proliferation of HER2+ tumor cell lines. A single administration of AAVrh.10αHER2 provided long-term therapeutic levels of anti-HER2 antibody expression without inducing an anti-idiotype response, suppressed the growth of HER2 tumors and increased the survival of tumor bearing mice. In the context that trastuzumab therapy requires frequent and repeated administration, this strategy might be developed as an alternate platform for delivery of anti-HER2 therapy.

KW - Adeno-associated virus

KW - Breast cancer

KW - Gene delivery

KW - Herceptin

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=77954819051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954819051&partnerID=8YFLogxK

U2 - 10.1038/cgt.2010.11

DO - 10.1038/cgt.2010.11

M3 - Article

C2 - 20448672

AN - SCOPUS:77954819051

VL - 17

SP - 559

EP - 570

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 8

ER -